Having reached a landmark agreement with Gilead Sciences Inc., Eva Pharma is proud to announce that it is now a licensed manufacturer for the antiviral treatment Remdesivir in 127 countries. 

This game-changing development establishes Eva Pharma’s position as a global leader in the battle against COVID-19. Accordingly, it will work at ‘full capacity’ while leveraging its far-reaching network to meet the onerous challenge of alacritously providing Remdesivir to all COVID-19 patients in 127 countries. 

“This license agreement comes at a critical time as the virus has started to spread in developing countries whose health-care systems are already severely strained. It is our duty to rise to the occasion and support our fellow man as humanity collectively strives to put an end to this pandemic. Eva Pharma is therefore working tirelessly and assiduously to ensure the availability of life-saving drugs to COVID-19 patients globally”, said Eva Pharma CEO, Riad Armanious.

EVA group and Gilead are highly successful partners, having fruitfully collaborated in the past to provide accessible, affordable and high-quality treatments of otherwise lethal infectious diseases such as HIV and hepatitis C to millions of patients in Africa. 

“We are thrilled to have been chosen to work side-by-side with Gilead sciences once more. We strongly believe that our partnership with Gilead will help us realize our vision of empowering the fight for health and well-being as a human right,’ said Armanious.

“Remdesivir” is an investigational new drug developed by Gilead Sciences. The treatment has recently been granted an emergency use authorization (EUA) to treat hospitalized COVID-19 patients in the U.S and the UK.

In addition, it is recommended for compassionate use in Europe and recently received regulatory approval in Japan. Two global clinical trials conducted to date have demonstrated positive results, reducing the recovery time for patients with COVID-19, although the full efficacy and safety of the treatment are still under investigation.

The agreement provides Eva pharma with Gilead’s technology, manufacturing process descriptions, specifications and methods in order to boost the production timeline of Remdesivir.

-ENDS-

About Gilead

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California. For more information on Gilead Sciences, please visit the company’s website at www.gilead.com. 

 

About Eva Pharma

Eva Pharma is leading international pharmaceutical company based in Cairo, Egypt and one of the fastest growing pharmaceutical company in the MENA region. The company has partnerships with some of the leading international pharmaceutical names the world over and has presence in 41 countries throughout the region. With a 3,000-strong team of some of the region’s most competent pharmaceutical professionals, Eva Pharma produces an average of 350,000 packs of more than 140 different drugs daily. Its state-of-the-art facilities are equipped with cutting-edge technology and are internationally recognized for innovation and the highest international quality standards. To learn more about Eva Pharma, please visit www.evapharma.com